Physicians' Academy for Cardiovascular Education

Inflammation & cardiovascular disease: Exploring new options for intervention

Sep. 10, 2013


Keep checking this site, as more presentations and webcasts related to the PACE Educational Programmes will be available in the near future.
 
As part of the ESC congress 2013, the PACE Foundation organised three EBAC Accredited Educational Programmes:

PCSK9: the new lipid target in preventive cardiology?

Inflammation & cardiovascular disease: Exploring new options for intervention

Early Initiation of antiplatelet therapy:Pre-treatment in ACS, facts and fictions
 

Via these EBAC-accredited educational programs, the PACE Foundation aims to help physicians to assimilate the proven findings of scientific research into the day-to-day practice of clinical medicine, aiming to improve outcomes in patients.
The symposium was co-chaired by Prof.dr. John Kastelein and Prof. dr. John E Deanfield.
 
Prof.dr. Peter Libby (Boston, MA, USA) gave a detailed overview of the biology of inflammation in atherosclerosis, and outlined several lines of evidence that point towards an involvement of inflammatory processes in all stages of atherosclerosis pathogenesis. Understanding of the mechanisms underlying inflammation in atherogenesis gives information on what biomarkers might be relevant to monitor risk and disease, as well as possible therapeutic targets.
 
Prof.dr. Wolfgang Koenig (Ulm, Germany) described biomarkers of inflammatory processes in cardiovascular disease in more detail. He presented the associations between C-reactive protein (CRP) levels and clinical outcomes, as well as the added value of measuring CRP levels to improve CV risk assessment. Especially in secondary prevention, CRP  can refine risk stratification. 
 
Now that most are convinced of the role of inflammation in the pathogenesis of cardiovascular disease, anti-inflammatory agents are under development to target and inhibit pro-inflammatory pathways, to limit atherosclerotic burden. Prof.dr. Paul Ridker (Boston, MA, USA) summarised recent evidence of the association between CRP and IL-6 levels and cardiovascular outcomes. He presented the aim and design of the ongoing CIRT and CANTOS trials that test an antibody targeting IL-1β and the anti-inflammatory rheumatoid arthritis drug methotrexate, respectively. Together with other phase II and III trials that test agents that modify inflammatory processes, these studies will shed light on whether treatments to prevent vascular disease should continue to focus solely on more aggressive LDL-c reduction, or whether there is room for therapies targeting the innate immune response.
 
The slides of these presentations are available on this website:
- Peter Libby: Inflammation biology in atherosclerosis
- Wolfgang Koenig: Biomarkers of inflammation and atherosclerotic risk
- Paul Ridker: Targeting inflammation in prevention of atherosclerotic events

Share this page with your colleagues and friends: